RVF and Other Emerging Infectious Diseases in East and Central Africa
NCT05139524 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000
Last updated 2021-12-01
Summary
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo
Conditions
- Rift Valley Fever
- Hemorrhagic Fevers, Viral
Interventions
- OTHER
-
Evidence of past or recent RVF exposure
Detection of RVF exposure.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Emory University
collaborator OTHER -
Washington University School of Medicine
collaborator OTHER -
Kenya Medical Research Institute
collaborator OTHER -
University of Nairobi
collaborator OTHER -
The International Livestock Research Institute (ILRI)
collaborator OTHER -
MRC/UVRI and LSHTM Uganda Research Unit
collaborator OTHER -
Sokoine University of Agriculture
collaborator OTHER -
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
collaborator OTHER -
Institute of Tropical Medicine, Belgium
collaborator OTHER -
Charite University, Berlin, Germany
collaborator OTHER -
Kenya Ministry of Health
collaborator OTHER_GOV -
Ministry of Agriculture Livestock Fisheries and Cooperatives, Kenya
collaborator UNKNOWN -
Ministry of Agriculture, Animal Industry and Fisheries, Uganda
collaborator UNKNOWN -
Ministry of Health, Uganda
collaborator OTHER_GOV -
Ministry of Public Health, Democratic Republic of the Congo
collaborator OTHER_GOV -
Ministry of Agriculture, Fisheries and Livestock, Democratic Republic of Congo
collaborator UNKNOWN -
Washington State University
lead OTHER
Principal Investigators
-
M. Kariuki Njenga, PhD · Washington State University
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-10-08
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- Democratic Republic of the Congo
- Kenya
- Tanzania
- Uganda
Study Locations
More Related Trials
-
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
NCT04099628 ·Status: COMPLETED ·Phase: NA
-
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
NCT05386875 ·Status: UNKNOWN
-
Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes
NCT06981442 ·Status: RECRUITING ·Phase: NA
-
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
NCT00906880 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
NCT00215267 ·Status: COMPLETED ·Phase: NA
-
Investigation of Fever Suspected as a Zoonosis Using Advanced Diagnostic Technologies
NCT04717622 ·Status: UNKNOWN
-
Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa
NCT01154907 ·Status: UNKNOWN
-
Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo
NCT02656862 ·Status: COMPLETED
-
Prevalence of LF Infection in Districts Not Included in LF Control Activities
NCT03131401 ·Status: COMPLETED
-
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
NCT05466630 ·Status: COMPLETED ·Phase: NA
-
Adoption of L-PZQ for Schistosomiasis by Endemic Counties - Social Science Research Study
NCT05350462 ·Status: ACTIVE_NOT_RECRUITING
-
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
NCT05749653 ·Status: COMPLETED ·Phase: NA
-
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
NCT05256017 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?
NCT02612896 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
NCT03356665 ·Status: COMPLETED ·Phase: NA
-
Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
NCT03852303 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria
NCT03394976 ·Status: WITHDRAWN
-
Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
NCT03874689 ·Status: COMPLETED
-
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
NCT06698510 ·Status: RECRUITING
-
Western Kenya Integrated COVID-19 Response
NCT04501458 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
NCT04035174 ·Status: WITHDRAWN ·Phase: NA
-
Epidemiology and Control of Mansonella Perstans Infection in Uganda
NCT00215280 ·Status: COMPLETED ·Phase: NA
-
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
NCT03052998 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
NCT00146627 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
NCT00127504 ·Status: COMPLETED ·Phase: PHASE2